Demuth Hans-Ulrich, Dijkhuizen Rick M, Farr Tracy D, Gelderblom Mathias, Horsburgh Karen, Iadecola Costantino, Mcleod Damian D, Michalski Dominik, Murphy Tim H, Orbe Josune, Otte Willem M, Petzold Gabor C, Plesnila Nikolaus, Reiser Georg, Reymann Klaus G, Rueger Maria A, Saur Dorothee, Savitz Sean I, Schilling Stephan, Spratt Neil J, Turner Renée J, Vemuganti Raghu, Vivien Denis, Yepes Manuel, Zille Marietta, Boltze Johannes
Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology (IZI-MWT), Halle/Saale, Germany.
Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht, The Netherlands.
Restor Neurol Neurosci. 2017;35(1):87-103. doi: 10.3233/RNN-160690.
The already established and widely used intravenous application of recombinant tissue plasminogen activator as a re-opening strategy for acute vessel occlusion in ischemic stroke was recently added by mechanical thrombectomy, representing a fundamental progress in evidence-based medicine to improve the patient's outcome. This has been paralleled by a swift increase in our understanding of pathomechanisms underlying many neurovascular diseases and most prevalent forms of dementia. Taken together, these current advances offer the potential to overcome almost two decades of marginally successful translational research on stroke and dementia, thereby spurring the entire field of translational neuroscience. Moreover, they may also pave the way for the renaissance of classical neuroprotective paradigms.This review reports and summarizes some of the most interesting and promising recent achievements in neurovascular and dementia research. It highlights sessions from the 9th International Symposium on Neuroprotection and Neurorepair that have been discussed from April 19th to 22nd in Leipzig, Germany. To acknowledge the emerging culture of interdisciplinary collaboration and research, special emphasis is given on translational stories ranging from fundamental research on neurode- and -regeneration to late stage translational or early stage clinical investigations.
重组组织型纤溶酶原激活剂静脉注射作为缺血性中风急性血管闭塞的再通策略已得到确立并广泛应用，最近又增加了机械取栓术，这代表了循证医学在改善患者预后方面的一项重大进展。与此同时，我们对许多神经血管疾病和最常见痴呆形式的发病机制的理解也迅速增加。总的来说，这些当前的进展为克服近二十年来中风和痴呆转化研究取得的微小成功提供了潜力，从而推动了整个转化神经科学领域的发展。此外，它们还可能为经典神经保护范式的复兴铺平道路。本综述报告并总结了神经血管和痴呆研究中一些最有趣且最有前景的近期成果。它重点介绍了4月19日至22日在德国莱比锡举行的第9届国际神经保护与神经修复研讨会上讨论的内容。为认可跨学科合作与研究的新兴文化，特别强调了从神经退行性变和再生的基础研究到后期转化或早期临床研究的转化案例。
